These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9269642)

  • 1. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
    Burke SK; Slatopolsky EA; Goldberg DI
    Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
    Goldberg DI; Dillon MA; Slatopolsky EA; Garrett B; Gray JR; Marbury T; Weinberg M; Wombolt D; Burke SK
    Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
    Rosenbaum DP; Holmes-Farley SR; Mandeville WH; Pitruzzello M; Goldberg DI
    Nephrol Dial Transplant; 1997 May; 12(5):961-4. PubMed ID: 9175050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
    Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
    Chertow GM; Dillon M; Burke SK; Steg M; Bleyer AJ; Garrett BN; Domoto DT; Wilkes BM; Wombolt DG; Slatopolsky E
    Clin Nephrol; 1999 Jan; 51(1):18-26. PubMed ID: 9988142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renagel: reducing serum phosphorus in haemodialysis patients.
    Burke SK
    Hosp Med; 2000 Sep; 61(9):622-7. PubMed ID: 11048603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renagel: a new and different phosphate binder.
    Ramsdell R
    ANNA J; 1999 Jun; 26(3):346-7. PubMed ID: 10633608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
    Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function.
    Heinrich T; Heidt H; Hafner V; Schmidt-Gayk H; Jenetzky E; Walter-Sack I; Mikus G; Bommer J
    Nephrol Dial Transplant; 2008 Sep; 23(9):2861-7. PubMed ID: 18388122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder.
    Nagano N; Miyata S; Obana S; Eto N; Fukushima N; Burke SK; Wada M
    Nephron; 2001 Nov; 89(3):321-8. PubMed ID: 11598397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
    J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.
    Tzanno-Martins C; Biavo BM; Ferreira-Filho O; Ribeiro-Junior E; João-Luiz MV; Degaspari S; Scavone C; Kawamoto E
    Int J Immunopathol Pharmacol; 2014; 27(1):25-35. PubMed ID: 24674676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
    Wilkes BM; Reiner D; Kern M; Burke S
    Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.
    Katopodis KP; Andrikos EK; Gouva CD; Bairaktari ET; Nikolopoulos PM; Takouli LK; Tzallas CS; Elisaf MS; Pappas MV; Siamopoulos KC
    Perit Dial Int; 2006; 26(3):320-7. PubMed ID: 16722024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel dosage forms and regimens for sevelamer-based phosphate binders.
    Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
    J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.